FREEHOLD, N.J. — February 26, 2026 — Leads & Copy —
Avalon GloboCare Corp. (NASDAQ: ALBT) has announced definitive agreements for a private placement expected to generate approximately $3.25 million before deductions.
The company will issue 6,372,550 shares of its common stock (or pre-funded warrants in lieu thereof), Series A-1 warrants to purchase up to an aggregate of 6,372,550 shares of common stock and Series A-2 warrants to purchase up to an aggregate of 6,372,550 shares of common stock, at a purchase price of $0.51 per share (or pre-funded warrant in lieu thereof) and associated warrants. H.C. Wainwright & Co. is the exclusive placement agent for the offering, priced at-the-market under Nasdaq rules.
The warrants will have an exercise price of $0.51 per share, exercisable upon stockholder approval of the issuance of shares. The Series A-1 warrants will expire five years from stockholder approval, and the Series A-2 warrants will expire eighteen months from stockholder approval.
Avalon intends to use the net proceeds to repay certain outstanding debt, for working capital, and for general corporate purposes. The company is a diversified entity focused on precision diagnostic consumer products and generative AI publishing and software.
The potential additional gross proceeds to the Company from the warrants, if fully-exercised on a cash basis, will be approximately $6.5 million. No assurance can be given that any of such warrants will become exercisable or will be exercised.
The offering is expected to close around February 27, 2026, pending customary closing conditions.
The securities were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended, and Regulation D. They have not been registered under the Act or state securities laws and may not be offered or sold in the United States without SEC registration or an applicable exemption. The securities were offered only to accredited investors. The Company has agreed to file one or more registration statements with the SEC covering the resale of the unregistered securities to be issued in the offering.
Avalon GloboCare Corp. is a technology-focused company developing and acquiring innovative artificial intelligence platforms. Through its AI-driven subsidiary, Avalon Quantum AI LLC, the Company is advancing next-generation AI systems, including automated video generation, enterprise documentation, and workflow automation solutions. Avalon is also expanding its intellectual property portfolio in cellular therapy and generative AI publishing and software. In addition, Avalon is marketing the KetoAir™ breathalyzer device, which is registered with the U.S. Food and Drug Administration as a Class I medical device, and plans to pursue additional diagnostic applications for the technology.
Source: Avalon GloboCare Corp.
